The U.S. Department of Health and Human Services is advancing a blueprint to speed early Rx development as part of Operation Trailblazer, aiming to reduce burdens for companies preparing first-in-human studies amid intensified international competition. The plan includes defining what data is necessary for Investigational New Drug filings, pushing more flexible trial protocol requirements, and piloting a faster consultation pathway with research institutions. The effort also explores ways to expand trial enrollment while considering compliance with anti-kickback laws. Industry expectations center on whether the “first-in-human” ramp-up becomes meaningfully faster without sacrificing safeguards for patient safety.